A brief review of 50 years of perioperative thrombosis and hemostasis management

Seminars in Hematology

Volumn 50, Issue 2, 2013, Pages 79-87

  Valsami, Serena ^a   Asmis, Lars M ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b Unilabs   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; DABIGATRAN; EDOXABAN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PRASUGREL; RIVAROXABAN; TICAGRELOR; TICLOPIDINE; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BONE MARROW TOXICITY; CEREBROVASCULAR ACCIDENT; COMPRESSION STOCKING; CORONARY ARTERY THROMBOSIS; DEEP VEIN THROMBOSIS; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DYSPNEA; ERYTHROCYTE TRANSFUSION; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HEMOSTASIS; HIP ARTHROPLASTY; HUMAN; KNEE ARTHROPLASTY; LOW DRUG DOSE; LUNG EMBOLISM; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PEROPERATIVE COMPLICATION; PREOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; VASCULAR DISEASE; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; EMBOLISM; HEMORRHAGE; HEMOSTASIS; HUMANS; RISK FACTORS; THROMBOSIS;

EID: 84884686415     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2013.04.001     Document Type: Article

References (86)

1. McLean J. The thromboplastic action of cephalin. Am J Physiol 1916, 41(2):250-257.
2. Abildgaard U. Highly purified antithrombin 3 with heparin cofactor activity prepared by disc electrophoresis. Scand J Clin Lab Invest 1968, 21(1):89-91.
3. Choay J. Biologic studies on chemically synthesized pentasaccharide and tetrasaccharide fragments. Semin Thromb Hemost 1985, 11(2):81-85.
4. Wallis R.B. Hirudins: from leeches to man. Semin Thromb Hemost 1996, 22(2):185-196.
5. Linkins L.-A., Dans A.L., Moores L.K., et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141(2 Suppl):e495S-e4530S.
6. Weismann R.E., Tobin R.W. Arterial embolism occurring during systemic heparin therapy. AMA Arch Surg 1958, 76(2):219-225.
7. Jack D.B. One hundred years of aspirin. Lancet 1997, 350(9075):437-439.
8. Craven L.L. Prevention of coronary and cerebral thrombosis. Miss Valley Med J 1956, 78(5):213-215.
9. Weiss H.J., Aledort L.M. Impaired platelet-connective-tissue reaction in man after aspirin ingestion. Lancet 1967, 2(7514):495-497.
10. Zucker M.B. ADP- and collagen-induced platelet aggregation in vivo and in vitro. Thromb Diath Haemorrh Suppl 1967, 26:175-184.
11. Smith J.B., Willis A.L. Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol 1971, 231(25):235-237.
12. Hamberg M., Svensson J., Wakabayashi T., Samuelsson B. Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proc Natl Acad Sci U S A 1974, 71(2):345-349.
13. Berger J.S., Brown D.L., Becker R.C. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med 2008, 121(1):43-49.
14. Baigent C., Blackwell L., Collins R., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009, 373(9678):1849-1860.
15. Tran H.A., Anand S.S., Hankey G.J., Eikelboom J.W. Aspirin resistance. Thromb Res 2007, 120(3):337-346.
16. Schomig A., Neumann F.J., Kastrati A., et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996, 334(17):1084-1089.
17. Love B.B., Biller J., Gent M. Adverse haematological effects of ticlopidine. Prevention, recognition and management. Drug Saf 1998, 19(2):89-98.
18. Shuldiner A.r., O'Connell J.R., Bliden K.P., et al. Association of cytochrome p450 2c19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009, 302(8):849-857.
19. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009, 119(19):2553-2560.
20. Tomasello S.D., Tello-Montoliu A., Angiolillo D.J. Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development. Expert Opin Investig Drugs 2011, 20(1):119-133.
21. Abergel E., Nikolsky E. Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome. Vasc Health Risk Manag 2010, 6:963-977.
22. Serebruany V.L. Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified. Thromb Haemost 2011, 105(5):752-759.
23. Bosch X., Marrugat J., Sanchis J. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes. Cochrane Database Syst Rev 2010, (9):CD002130.
24. Beck E.A. [Unexpected hemorrhage in surgery]. Schweiz Med Wochenschr 1975, 105(24):775-777.
25. Eika C., Havig O., Godal H.C. The value of preoperative haemostatic screening. Scand J Haematol 1978, 21(4):349-354.
26. Rohrer M.J., Michelotti M.C., Nahrwold D.L. A prospective evaluation of the efficacy of preoperative coagulation testing. Ann Surg 1988, 208(5):554-557.
27. Macpherson C.R., Jacobs P., Dent D.M. Abnormal peri-operative haemorrhage in asymptomatic patients is not predicted by laboratory testing. S Afr Med J 1993, 83(2):106-108.
28. Houry S., Georgeac C., Hay J.M., Fingerhut A., Boudet M.J. A prospective multicenter evaluation of preoperative hemostatic screening tests. The French Associations for Surgical Research. Am J Surg 1995, 170(1):19-23.
29. Peterson P., Hayes T.E., Arkin C.F., et al. The preoperative bleeding time test lacks clinical benefit: College of American Pathologists and American Society of Clinical Pathologists position article. Arch Surg 1998, 133(2):134-139.
30. Biron C., Mahieu B., Rochette A., et al. Preoperative screening for von Willebrand disease type 1: low yield and limited ability to predict bleeding. J Lab Clin Med 1999, 134(6):605-609.
31. Eckman M.H., Erban J.K., Singh S.K., Kao G.S. Screening for the risk for bleeding or thrombosis. Ann Intern Med 2003, 138(3):W15-W24.
32. Koscielny J., von Tempelhoff G.-F., Ziemer S., et al. A practical concept for preoperative management of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 2004, 10(2):155-166.
33. Koscielny J., Ziemer S., Radtke H., et al. A practical concept for preoperative identification of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 2004, 10(3):195-204.
34. Houry S., Georgeac C., Hay J.-M., Fingerhut A., Boudet M.-J. A prospective multicenter evaluation of preoperative hemostatic screening tests. Am J Surg 1995, 170(1):19-23.
35. Pfanner G., Koscielny J., Pernerstorfer T., et al. Präoperative Blutungsanamnese. Anaesthesist 2007, 56(6):604-611.
36. Tosetto A., Rodeghiero F., Castaman G., et al. A quantitative analysis of bleeding symptoms in type 1?von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006, 4(4):766-773.
37. Kozek-Langenecker S.A. Anästhesie. Moderne präoperative Gerinnungsabklärung und Outcome. Wiener klinisches Magazin 2010, 13(5):28.
38. Geerts W.H., Pineo G.F., Heit J.A., et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126(3 Suppl):338S-400S.
39. Monreal M., Lafoz E., Navarro A., et al. A prospective double-blind trial of a low molecular weight heparin once daily compared with conventional low-dose heparin three times daily to prevent pulmonary embolism and venous thrombosis in patients with hip fracture. J Trauma 1989, 29(6):873-875.
40. Lieberman J.R., Wollaeger J., Dorey F., et al. The efficacy of prophylaxis with low-dose warfarin for prevention of pulmonary embolism following total hip arthroplasty. J Bone Joint Surg 1997, 79(3):319-325.
41. Robinson K.S., Anderson D.R., Gross M., et al. Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the Post-Arthroplasty Screening Study: a randomized, controlled trial. Ann Intern Med 1997, 127(6):439-445.
42. Leclerc J.R., Gent M., Hirsh J., Geerts W.H., Ginsberg J.S. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group. Arch Intern Med 1998, 158(8):873-878.
43. Kearon C. Duration of venous thromboembolism prophylaxis after surgery. Chest 2003, 124(6 Suppl):386S-392S.
44. Douketis J.D., Spyropoulos A.C., Spencer F.A., et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141(2 Suppl):e326S-e350S.
45. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965, 13:516-530.
46. Esmon C.T., Stenflo J., Suttie J.W. A new vitamin K-dependent protein. A phospholipid-binding zymogen of a serine esterase. J Biol Chem. 25 1976, 251(10):3052-3056.
47. Griffin J.H., Evatt B., Zimmerman T.S., Kleiss A.J., Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981, 68(5):1370-1373.
48. Comp P.C., Nixon R.R., Cooper M.R., Esmon C.T. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984, 74(6):2082-2088.
49. Bertina R.M., Koeleman B.P., Koster T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994, 369(6475):64-67.
50. Poort S.R., Rosendaal F.R., Reitsma P.H., Bertina R.M. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996, 88(10):3698-3703.
51. Rosendaal F.R., Siscovick D.S., Schwartz S.M., Psaty B.M., Raghunathan T.E., Vos H.L. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997, 90(5):1747-1750.
52. Hughes G.R. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. BMJ 1983, 287(6399):1088-1089.
53. Miyakis S., Lockshin M.D., Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4(2):295-306.
54. Keeling D., Mackie I., Moore G.W., Greer I.A., Greaves M. British Committee for Standards in Hematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012, 157(1):47-58.
55. Fleming H.A., Bailey S.M. Massive pulmonary embolism in healthy people. Br Med J 1966, 1(5499):1322-1327.
56. Snell A.M. The relation of obesity to fatal postoperative pulmonary embolism. Arch Surg 1927, 15:237-244.
57. Stein P.D., Beemath A., Olson R.E. Obesity as a risk factor in venous thromboembolism. Am J Med 2005, 118(9):978-980.
58. Allman-Farinelli M.A. Obesity and venous thrombosis: a review. Semin Thromb Hemost 2011, 37(8):903-907.
59. Phlegmatia alba dolens. Clinique Médicale de l'Hotel Dieu de Paris 1865, 2nd ed. A. Trousseau (Ed.).
60. Khorana A.A., Francis C.W., Culakova E., Lyman G.H. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005, 104(12):2822-2829.
61. Odell W.D. An analysis of the reported association of oral contraceptives to thromboembolic disease. West J Med 1975, 122(1):26-33.
62. Meade T.W. Hormone replacement therapy and haemostatic function. Thromb Haemost 1997, 78(1):765-769.
63. Kaatz S., Douketis J.D., Zhou H., Gage B.F., White R.H. Risk of stroke after surgery in patients with and without chronic atrial fibrillation. J Thromb Haemost 2010, 8(5):884-890.
64. Tinmouth A., Morrow B., Cruickshank M., Moore P., Kovacs M. Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis. Ann Pharmacother 2001, 35(6):669-674.
65. Siegal D., Yudin J., Kaatz S., Douketis J.D., Lim W., Spyropoulos A.C. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 2012, 126(13):1630-1639.
66. Schmidt P.J. The plasma wars: a history. Transfusion 2012, 52(Suppl 1):2S-4S.
67. Pool J.G., Shannon A.E. Production of high-potency concentrates of antihemophilic globulin in a closed-bag system. N Engl J Med 1965, 30;273(27):1443-1447.
68. Murphy S., Gardner F.H. Platelet preservation. N Engl J Med 1969, 280(20):1094-1098.
69. Alter H.J., Holland P.V., Purcell R.H., et al. Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. Ann Intern Med 1972, 77(5):691-699.
70. Evatt B.L., Gomperts E.D., McDougal J.S., Ramsey R.B. Coincidental appearance of LAV/HTLV-III antibodies in hemophiliacs and the onset of the AIDS epidemic. N Engl J Med 1985, 312(8):483-486.
71. Kuo G., Choo Q., Alter H., et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989, 244(4902):362-364.
72. Alter H.J., Klein H.G. The hazards of blood transfusion in historical perspective. Blood 2008, 112(7):2617-2626.
73. Vamvakas E.C., Blajchman M.A. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009, 113(15):3406-3417.
74. Doyle S., O'Brien P., Murphy K., Fleming C., O'Donnell J. Coagulation factor content of solvent/detergent plasma compared with fresh frozen plasma. Blood Coagul Fibrinolysis 2003, 14(3):283-287.
75. Marik P.E., Corwin H.L. Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Crit Care Med 2008, 36(9):2667-2674.
76. Palmieri T.L., Caruso D.M., Foster K.N., et al. Effect of blood transfusion on outcome after major burn injury: a multicenter study. Crit Care Med 2006, 34(6):1602-1607.
77. Hébert P.C., Wells G., Blajchman M.A., et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999, 340(6):409-417.
78. Sarani B., Dunkman W.J., Dean L., Sonnad S., Rohrbach J.I., Gracias V.H. Transfusion of fresh frozen plasma in critically ill surgical patients is associated with an increased risk of infection. Crit Care Med 2008, 36(4):1114-1118.
79. Watson G.A., Sperry J.L., Rosengart M.R., et al. Fresh frozen plasma is independently associated with a higher risk of multiple organ failure and acute respiratory distress syndrome. J Trauma 2009, 67(2):221-227.
80. Spinella P.C., Perkins J.G., Grathwohl K.W., et al. Effect of plasma and red blood cell transfusions on survival in patients with combat related traumatic injuries. J Trauma 2008, 64(2 Suppl):S69-S77.
81. Shander A., Van Aken H., Colomina M.J., et al. Patient blood management in Europe. Br J Anaesth 2012, 109(1):55-68.
82. Weber C.F., Gorlinger K., Meininger D., et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology 2012, 117(3):531-547.
83. Theusinger O.M., Madjdpour C., Spahn D.R. Resuscitation and transfusion management in trauma patients: emerging concepts. Curr Opin Crit Care 2012, 18(6):661-670.
84. Rahe-Meyer N., Solomon C., Hanke A., et al. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. Anesthesiology 2013, 118(1):40-50.
85. Hofmann A., Farmer S., Towler S.C. Strategies to preempt and reduce the use of blood products: an Australian perspective. Curr Opin Anaesthesiol 2012, 25(1):66-73.
86. Makris M., Van Veen J.J., Tait C.R., Mumford A.D., Laffan M. The British Committee for Standards in H. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol 2013, 160(1):35-46.